Home Tools
Log in
Cart

Search Result

Search Results for " hexamethonium "

8

Compounds

Cat No. Product Name Synonyms Targets
T0287 Hexamethonium Bromide Gangliostat,Simpatoblock,Hexamethonium Dibromide Apoptosis , Dopamine Receptor , AChR
Hexamethonium Bromide (Hexamethonium Dibromide), a specific antagonist of neuronal-type nicotinic AChR in ganglia, is poorly absorbed from the gastrointestinal tract and does not cross the blood-brain barrier.
T69939 Hexamethonium tartrate
Hexamethonium tartrate is a nicotinic cholinergic antagonist often referred to as the prototypical ganglionic blocker. It is poorly absorbed from the gastrointestinal tract and does not cross the blood-brain barrier. It ...
T69023 Hexamethonium chloride
Hexamethonium chloride is a preferential nicotinic receptor blocker at the level of autonomic ganglia. It has been shown to cross the blood-brain barrier only in high doses.
T70269 Hexamethonium chloride dihydrate
Hexamethonium chloride dihydrate is a non-depolarizing NMJ blocker and nAChR antagonist. It has previously been used to treat hypertension. It inhibits sympathetic nervous system activity and acts as a skeletal muscle re...
T69022 Hexamethonium Free Base
Hexamethonium Free Base is a nicotinic cholinergic antagonist often referred to as the prototypical ganglionic blocker. It is poorly absorbed from the gastrointestinal tract and does not cross the blood-brain barrier. It...
T68645 Hexamethonium monotartrate
Hexamethonium monotartrate is a non-depolarizing NMJ blocker and nAChR antagonist. It has previously been used to treat hypertension. It inhibits sympathetic nervous system activity and acts as a skeletal muscle relaxant...
T69161 Hexamethonium bromide dihydrate
Hexamethonium bromide dihydrate is a non-depolarizing NMJ blocker and nAChR antagonist. It has previously been used to treat hypertension. It inhibits sympathetic nervous system activity and acts as a skeletal muscle rel...
T69938 Befiradol fumarate
Befiradol fumarate is a highly selective and potent 5-HT1A receptor agonist potentially for the treatment of drug-induced dyskinesia in patients with Parkinson's disease.
TargetMol